Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Read More

Research & Applied Markets

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
Read More

Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
Learn More

Luminex® Blog

METHODS Special Issue: To Parse Inflammation, Scientists Pair Multiplex and Single-Molecule Techniques

A hybrid strategy offers the best of both worlds, revealing mechanisms of injury response

In a recent publication, scientists exploring the relationship between systemic inflammation and peripheral muscle injury report the successful combination of bead-based multiplexing with single-molecule counting technology to evaluate the body’s response to exercise. The paper, released in Methods, comes from scientists at the University of North Texas.

Continue Reading >

xMAP® Technology Overview



xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.

Watch more videos >

Luminex on Twitter

Seeking to reveal the mechanisms of inflammatory response during extreme exercise, researchers at @UNTsocial Applie…
h J R
"People hear the talks, they hear about the technology, they ask us about the possibilities & they are really excit…
h J R
Amnis: The Rolls Royce of flow? Taylor thinks so. Our Seattle-based QA manager is super enthiusiastic about our new…
h J R

Latest News

31 July
Luminex Corporation Reports Second Quarter 2019 Financial Results And Increase In Quarterly Dividend

11 July
Luminex Corporation Second Quarter Earnings Release Scheduled for July 31, 2019

1 July
Luminex Submits ARIES MRSA Assay for FDA Clearance

21 May
Luminex Corporation Declares Second Quarter Cash Dividend

14 May
Luminex Corporation to Present at Upcoming Healthcare Investor Conferences


UKEV Summer School 2019
16-19 July
Nottingham, UK

3-4 September
Zurich, Switzerland

11-14 September
Copenhagen, Denmark